Latest Forum Topics / Biosensors | Post Reply |
Is Biosensors a good buy?
|
||||||||||||||||||||||||||
novena_33
Veteran |
22-Apr-2008 11:46
|
|||||||||||||||||||||||||
x 0
x 0 Alert Admin |
Get that man a tiger....... |
|||||||||||||||||||||||||
Useful To Me Not Useful To Me | ||||||||||||||||||||||||||
bengster68
Master |
22-Apr-2008 11:41
|
|||||||||||||||||||||||||
x 0
x 0 Alert Admin |
Frankly im not sure if Terumo is already a BIG shareholder. Someone mentioned Jap fund houses are buying some time ago. Im not sure if this rumour is credible or not but anything can happen. Any shareholding below 5% no need to be disclosed to SGX. But if Im Terumo, i will be worried if BIG kena taken over by a bigger DES rival. This is because my licensing agreement only have abnother 5 years and i will be kicked out after 5 years. I believe Terumo is fully aware of how good BIG's DES technology really is and willing to pay US$40m cash upfront. I think their NOBORI (Biomatrix) DES can have a life-span of about 10 years. So if a rival buy over BIG, their licensing will definitely stop at 5 years and thats it. I think Terumo may have to do something about their NOBORI's future. |
|||||||||||||||||||||||||
Useful To Me Not Useful To Me | ||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
bengster68
Master |
22-Apr-2008 11:29
|
|||||||||||||||||||||||||
x 0
x 0 Alert Admin |
This US$40m cash is only for Terumo's CE markets (excluding Japan). Maybe we will see another US$40m cash for Terumo's exclusive Japan market soon??? BIOSENSORS!!!!!!!!!!!!! CHEEEEONG!!!!!!!!!!!!!!!!!! ARRGGGGHHHH!!!!!!!!!!!!!!!!!!!!! |
|||||||||||||||||||||||||
Useful To Me Not Useful To Me | ||||||||||||||||||||||||||
novena_33
Veteran |
22-Apr-2008 11:27
|
|||||||||||||||||||||||||
x 0
x 0 Alert Admin |
thanks Bengster....... for spending your time and puting in effort to explain to us........ if the Big Boys are paying collecting at that type of price.....hummm...what will be their TP....... so Bengster...what ur take? no $2 no selll........ |
|||||||||||||||||||||||||
Useful To Me Not Useful To Me | ||||||||||||||||||||||||||
JunVic
Member |
22-Apr-2008 11:27
|
|||||||||||||||||||||||||
x 0
x 0 Alert Admin |
Haha, I like this counter, coz i can get information faster n easier through this forum Huat Ah!!!!!!!!! |
|||||||||||||||||||||||||
Useful To Me Not Useful To Me | ||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
bengster68
Master |
22-Apr-2008 11:22
|
|||||||||||||||||||||||||
x 0
x 0 Alert Admin |
Terumo would love to but i think they cannot do it alone financially. Anyway, where is the cheering??? Let me start the ball rolling first............ CASH!!! CASH!!! CASH AHHH!!!! HUAT!!! HUAT!!! HUAT ARGGGGHH!!!! US$40M CASH LAI LIAO AHHH!!!!!!!! |
|||||||||||||||||||||||||
Useful To Me Not Useful To Me | ||||||||||||||||||||||||||
showmedamoney
Member |
22-Apr-2008 11:04
|
|||||||||||||||||||||||||
x 0
x 0 Alert Admin |
Hmm? Are you suggesting that the Terumo is a likely takeover candidate too? I always thought it would be some pharmacuetical giant like JNJ, and that Terumo and Biosensors were just partners. Anyway i hope the trade halt will be lifted after lunch. Don't be like the last halt which was something like 3 days.. by then everybody lost interest already.. |
|||||||||||||||||||||||||
Useful To Me Not Useful To Me | ||||||||||||||||||||||||||
bengster68
Master |
22-Apr-2008 10:59
|
|||||||||||||||||||||||||
x 0
x 0 Alert Admin |
I think what BIG did is a good corporate move. BIG monetise the future profit now, boost up their share price first and hold more cash now for future expansion. BIG now has only US$60m cash. How to go to takeover negotitaions a few months later with such low cash levels? Will kena squeezed by big boys like JNJ. When the big boys know you have low cash levels, they know you are more desperate to sell, then they will squeeze you for a lower price. With this US$40m cash added, BIG should be holding US$100m cash. This is a more respectable figure and JNJ knows BIG can survive extremely well with this money for at least 5 years. Plus, Biomatrix is already approved so can start to bring in sales, profits and more cash. BIG will become a bigger threat to existing DES rivals. Actually US$100m cash level is still not respectable enough. US$150m will be even more beautiful as there will be more than enough cash to fund all kinds of global expansion and DES rivals will be more worried. BIG has the best DES technology and give them more financial muscle, BIG can really wreck a lot of havoc for the other existing players. When JNJ takeover Conor, Conor was holding US$100m cash. I expect to see more of such deals with the other 2 licensees Xtent and Devax. I think they should be getting their CE Mark somewhere middle of 2008. | |||||||||||||||||||||||||
Useful To Me Not Useful To Me | ||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
bengster68
Master |
22-Apr-2008 10:46
|
|||||||||||||||||||||||||
x 0
x 0 Alert Admin |
U think the Japs bought into BIG already? I suspect they could be holding 4.9% liao. |
|||||||||||||||||||||||||
Useful To Me Not Useful To Me | ||||||||||||||||||||||||||
showmedamoney
Member |
22-Apr-2008 10:41
|
|||||||||||||||||||||||||
x 0
x 0 Alert Admin |
The announcement is out.. Terumo will pay Biosensors US$40 million within the next 30 days as part of an amendment to the contract between the two companies. I guess this is good news, since it kinda suggests that Terumo thinks they will make more money by paying a lump sum first, and reducing the profit sharing over the next 5 years. And if they think paying US$40m is a good deal, just imagine how much they've calculated their profits will be. Bear in mind, Terumo only has sole distributorship in Japan. Then again, announcements like these make me think that a takeover is quite unlikely, since Biosensors seem to have really big plans for the future. That is unless some company offers a really ridiculous price. |
|||||||||||||||||||||||||
Useful To Me Not Useful To Me | ||||||||||||||||||||||||||
A02041315
Senior |
22-Apr-2008 10:28
|
|||||||||||||||||||||||||
x 0
x 0 Alert Admin |
Bro. Beng, I think you can arrange the Japanese Suhsi lunch liao.May be your Japanese friends back liao. BIG!!!!!!!!!!!!!CHIONG!!!!!!!!!!!!!!!!!!AR!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! |
|||||||||||||||||||||||||
Useful To Me Not Useful To Me | ||||||||||||||||||||||||||
jackjames
Elite |
22-Apr-2008 10:24
|
|||||||||||||||||||||||||
x 0
x 0 Alert Admin |
i disagree. there are many single HUGE transaction buy up throughout the last 2 weeks. Did you realize? |
|||||||||||||||||||||||||
Useful To Me Not Useful To Me | ||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
Maxximo
Member |
22-Apr-2008 10:06
|
|||||||||||||||||||||||||
x 0
x 0 Alert Admin |
This BIG is real good. Not even a bit of price movement before annoucement. Must be something highly confidential & signifcant or maybe just wan to announce the date of result release due next month. Hopefully it will be good. Cheers. |
|||||||||||||||||||||||||
Useful To Me Not Useful To Me | ||||||||||||||||||||||||||
AK_Francis
Supreme |
22-Apr-2008 10:01
Yells: "Happy go lucky, cheers." |
|||||||||||||||||||||||||
x 0
x 0 Alert Admin |
Beng, you are kind enough to make old man life better. Tks again and hope to hear from you more, other than BIG, ha ha. |
|||||||||||||||||||||||||
Useful To Me Not Useful To Me | ||||||||||||||||||||||||||
allright
Senior |
22-Apr-2008 09:56
|
|||||||||||||||||||||||||
x 0
x 0 Alert Admin |
Thank YOU for the clear explanation. Any news when the halt will be lifted? | |||||||||||||||||||||||||
Useful To Me Not Useful To Me | ||||||||||||||||||||||||||
bengster68
Master |
22-Apr-2008 09:52
|
|||||||||||||||||||||||||
x 0
x 0 Alert Admin |
Essence of the BSX article relevent to BIG is the top 2 DES players are losing market share due to general decline of DES due to safety concerns on blood-clot issues (i believe most likely in USA) and emergence of newer DES players (MDT and ABT) eating into their market share. BIG and Terumo will soon eat into their market share as well. Plus, Xience and Endeavor got FDA approval so we will see even more decline in DES sales from the current top 2 players BSX and JNJ. Asia from what i know is still experiencing DES sales growth. So BIG is in a good position to capture this new emerging Asia market. For 1Q2008, JNJ lost 24% sales of Cypher and BSX lost about 9% of Taxus sales compared to 1Q2007. | |||||||||||||||||||||||||
Useful To Me Not Useful To Me | ||||||||||||||||||||||||||
AK_Francis
Supreme |
22-Apr-2008 09:24
Yells: "Happy go lucky, cheers." |
|||||||||||||||||||||||||
x 0
x 0 Alert Admin |
Yeoh, Bengster pse insert Chinese sub-title as well, ha ha ha. AK old, long sided plus Chinese edu lah. But those stuff will KIV, may later of the day then to digest further, good work lah. Now, though market is quiet but once a while go in to tab the pulses, as SPC Kepcorp and Kepld XD soon. Must trace the trends before dump or keep loh. Money is queen leow. Cheers. | |||||||||||||||||||||||||
Useful To Me Not Useful To Me | ||||||||||||||||||||||||||
allright
Senior |
22-Apr-2008 09:15
|
|||||||||||||||||||||||||
x 0
x 0 Alert Admin |
Bengster, so can you tell us in English(hahaha) is this good for biosensors hahahaha? You think the trading Halt is good news? Aya always so happy when halted and hope so much.This time HOPE we dont get disappointed . |
|||||||||||||||||||||||||
Useful To Me Not Useful To Me | ||||||||||||||||||||||||||
bengster68
Master |
22-Apr-2008 09:08
|
|||||||||||||||||||||||||
x 0
x 0 Alert Admin |
This article explains BSX's results a bit better: Expense cuts help Boston Scientific post $322M 1Q profit Monday April 21, 6:59 pm ET By Mark Jewell, AP Business Writer BOSTON (AP) -- Boston Scientific Corp.'s first-quarter profit more than doubled as the medical device maker cut expenses to offset declining sales of drug-coated heart stents.
The Natick, Mass.-based company said Monday it posted net income of $322 million, or 21 cents per share, in the January-March period, compared with a profit of $120 million, or 8 cents per share, in the same period a year ago. Net sales fell slightly to $2.05 billion from $2.09 billion a year earlier. Both comparison figures included sales from five businesses that Boston Scientific recently sold to reduce debt from its $27 billion acquisition of Guidant Corp. two years ago. The results were clouded by one-time charges and tax gains from the asset sales, and from Boston Scientific's elimination of 2,300 jobs, or 8 percent of its work force. Analysts surveyed by Thomson Financial forecast a profit of 11 cents per share in the latest period, but it was unclear whether that estimate included all the one-time items that Boston Scientific counted. The biggest were a $114 million after-tax gain from the sale of five businesses, and $143 million in after-tax amortization expense. Excluding such items, Boston Scientific's profit was $357 million, or 24 cents per share, up from $262 million, or 17 cents per share, a year ago. "We continued to make good progress during the quarter, particularly in our efforts to bring expenses in line with revenues," said Jim Tobin, Boston Scientific's president and chief executive officer. Boston Scientific expects to post a second-quarter profit of 14 cents to 19 cents per share -- excluding one-time items -- on sales of $1.95 billion to $2.075 billion. Analysts expected a profit of 12 cents per share on sales of $2.02 billion. Boston Scientific released its earnings after its shares rose 38 cents, or 3 percent, to close at $13.03. In after-hours trading, the stock gained another 67 cents. Sales of Boston Scientific's drug-coated heart stents fell nearly 9 percent to $428 million in the latest quarter from $468 million a year earlier. Use of drug-coated stents to prop coronary arteries open after plaque-clearing surgery has declined amid research data questioning the devices' safety and effectiveness compared with older bare-metal versions, although some more recent studies have called those findings into question. The safety concerns have reduced the number of stent procedures at a time when prices have declined amid growing competition from new players in the drug-coated stent market. Last week, Boston Scientific's chief drug-coated stent rival, Johnson & Johnson, reported a 24 percent decline in sales of its Cypher stent, sharper than the 9 percent decline for Boston Scientific's Taxus. Despite the U.S. regulators' approval of Medtronic Inc.'s Endeavor stent in February, Tobin said Boston Scientific "held our (drug-coated stent) leadership positions in both the U.S. and worldwide markets." Sales of implanted defibrillators rose 3 percent in the latest quarter to $411 million from $398 million a year earlier. That market has only recently begun to recover from a series of safety-related recalls a few years ago. Chris Cooley, an analyst with FTN Midwest Securities, said Boston Scientific's cost-cutting appeared to be helping the company's bottom line a bit faster than expected. But Cooley called the company's stent and defibrillator results "a little disappointing," because those results were boosted more by international sales gains and the weak dollar than U.S. sales trends. In addition, a defibrillator rival, St. Jude Medical Inc., last week reported a far healthier first-quarter defibrillator sales gain of 20 percent, compared with Boston Scientific's 3 percent increase. |
|||||||||||||||||||||||||
Useful To Me Not Useful To Me | ||||||||||||||||||||||||||
bengster68
Master |
22-Apr-2008 08:52
|
|||||||||||||||||||||||||
x 0
x 0 Alert Admin |
OMG!!!!! Whats up???? Got takeover offer??? |
|||||||||||||||||||||||||
Useful To Me Not Useful To Me |